Mehtap NİSARİ, Harun ÜLGER, Yasemin Torun ALTUNER, Mehmet Akif ÖZDEMİR, Zuhal HAMURCU

BİR İLAÇ OLAN ANKAFERD BLOOD STOPPER'IN İNSAN UMBİLİKAL VEN ENDOTEL HÜCRE KÜLTÜRÜNE ETKİSİ

Giriş: Ankaferd kanama durdurucu (ABS) tıbbi bitki ekstraksiyonudur. ABS Thymus vulgaris, Glicirhiza glabra, Vitis vinifera, Alpinia officinarum ve Urtica dioica bitkilerinin standardize edilmiş bir karışımıdır. Bu çalışmanın amacı in vitro endotel hücre çoğalmasının ABS'nin farklı zaman ve dozlarının in vitro apoptotik etkilerini araştırmaktır. Gereç ve yöntem: Erciyes Üniversitesi Hastanesinde sezeryanla yapılan doğumlardan alınan göbek bağı toplardamarı PBS ile yıkandıktan sonra içine yaklaşık 10 mg/ml kollajenaz verildi ve 10 dakika 37ºC de inkübatörde bekletildi. Damar içerisindeki hücre ve kollajenaz karışımı tüp içine alındıktan ve 30 ml besi yeri ilave edildikten sonra 1000 rpm’de 10 dakika santrifüj edildi. Üstteki supernatant atıldı ve tüpün dip kısmında biriken hücreler üzerine 2 ml besi yeri ilave edilerek karıştırıldı ve 25 cm’lik flasklara ekildi. Thoma lamında sayılan hücreler gruplara ayrılarak her bir gruba ait kültür ortamına sırasıyla 5 µl, 25 µl and 50 µl ABS 24 saat uygulandı. Daha sonra hücrelerin canlılığı ve/veya proliferasyonu MTS testi ile tespit edildi. Bulgular: Doza bağlı olarak deney grubu hücrelerinde bir artışın olduğu görüldü. Kontrol ve deney gruplarından elde edilen ortalama hücre sayısı sırasıyla 7,68x103 (±1,7), 5,56x103(±1,09) 4,12x103(±1,14) ve 2,43x103(±0,89) idi. Deney gruplarının kontrol grubu ile karşılaştırıldığında deney gruplarındaki azalma istatistiksel olarak anlamlıydı (p

The Effect of Ankaferd Blood Stopper as a Drug On Human Umbilical Vein Endothelial Cell Culture(HUVEC)

Introduction: Ankaferd Blood Stopper (ABS) is an herbal extract. ABS comprises of standardized mixture ofherbs T. vulgaris, G. glabra, V. vinifera, A. officinarum and U. dioica. The aim of this study was to investigatethe in vitro apoptotic effects of the different times and doses of ABS on in vitro endothelial cell proliferation.Methods: Umbilical cord obtained at Caesarean sections from Erciyes University hospital. After washingPBS, the cord vein lumen was filled with PBS containing 10 mg/ml collagenase and incubated 10 minuteat 37°C. The contents of the vein were flushed out with 30 ml medium collected in centrifuge tube thencentrifugated at 1000 rpm for 10 minute. The cells were plated in 2 ml of medium at T-25 plastic flasks. Theendothelial cells were incubated with only medium in control group and different concentrations of ABS (5µl, 25 µl and 50 µl ABS) in the experimental groups for 24 h. Then the viability and/or proliferation of cellswere detected by MTS assay.Results: The mean cell number were obtained from the control and experimental groups 7,68x103 (±1,7),5,56x103(±1,09) 4,12x103(±1,14), and 2,43x103(±0,89) respectively. The cells of the experimental groups compared with the control group to the decrease in experimental groups was statistically significant(p

PDF

___

1. Dinçol ME, Ozbas H, Yılmaz B, Ersev H, Gokyay S and Olgac V. Effect of the plant-based hemostatic agent Ankaferd Blood Stopper on the biocompatibility of mineral trioxide aggregate. BMC Oral Health 2016; 16: 111.
2. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu İC. Evaluation of Hemostatic Effects of Ankaferd as an Alternative Medicine. Altern Med Rev 2010; 15(4): 329-336.
3. Huri E, Haznedaroglu IC, Akgul T, Astarci M, Ustun H, Germiyanoulu C. Biphasic effects of ankaferd blood stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage. Saudi Med J. 2010; 31(8): 864-8.
4. Yılmaz E, Güleç Ş, Torun D, Haznedaroğlu İC, Akar N. The effects of Ankaferd Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turk J Hematol 2011; 28: 276-85.
5. Arslan S, Haznedaroglu IC, Oz B, Goker H. Endobronchial application of Ankaferd blood stopper to control profuse lung bleeding leading to hypoxemia and hemodynamic instability. Respiratory Medicine 2009; 2: 144-6.
6. Kurt M, Akdogan M, Onal IK, Kekilli M, Arhan M, Aksu S, Kurt OK, Haznedaroglu IC. Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: a retrospective analysis. Dig Liver Dis 2010; 42: 196-9.
7. Lang I, Pabst M.A, Hiden U, Blaschitz A., Dohr G, Hahn T, Desoye G. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur J Cell Biol 2003; 82(4): 163–173.
8. Ribatti D, Nico B, Vacca A, Roncali L, Dammacco F. Endothelial cell heterogeneity and organ specificity. J Hemototherap Stem Cell Res 2002; 11: 81–90.
9. Aird, W.C. Phenotypich heterogeneity of the endothelium: I.Structure, function, and mechanisms. Circ Res 2007; 100: 158–173.
10. Schechner JS, Nath AK, Zheng L, et al. In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse. Proc Natl Acad Sci USA 2000: 97: 9191–9196.
11. Zheng L, Dengler TJ, Kluger MS, et al. Cytoprotection of human umbilical vein endothelial cells against apoptosis and CTL mediated lysis provided by caspase-resistant Bcl-2 without alterations in growth or activation responses. J Immunol, 2000; 164: 4665–4671.
12. Enis DR, Shepherd BR, Wang Y, et al. Induction, differentiation, and remodeling of blood vessels after transplantation of Bcl2-transduced endothelial cells. Proc Natl Acad Sci USA 2005; 102: 425–430.
13. Levenberg S, Rouwkema J, Macdonald M, et al. Engineering vascularized skeletal muscle tissue. Nat Biotechnol 2005; 23: 879–884.
14. Kelm JM, Djonov V, Hoerstrup SP, et al. Tissue-transplant fusion and vascularization of myocardial microtissues and macrotissues implanted into chicken embryos and rats. Tissue Eng 2006; 12: 2541–2553.
15. Shepherd BR, Enis DR, Wang F, Suarez Y, Pober JS, Schechner JS. Vascularization and engraftment of a human skin substitute using circulating progenitor cell-derived endothelial cells. FASEB J 2006; 1739–1741.
16. Rouwkema J, De Boer J, Van Blitterswijk CA. Endothelial cells assemble into a 3-dimensional prevascular network in a bone tissue engineering construct. Tissue Eng 2006; 12: 2685–2693.
17. Mihmanli A, Ulker Z, Alpsoy L, Ezirganli S. Evaluation of cytotoxicity of a new hemostatic agent Ankaferd blood stopper using different assays. Hum Exp Toxicol 2012; 31: 780-787.
18. Turhan N, Kurt M, Shorbagi A, et al. Topical Ankaferd Blood Stopper administration to bleeding gastrointestinal carcinomas decreases tumor vascularization. Am J Gastroenterol 2009; 104: 2874-2877.
19. Ozaslan E, Purnak T, Yildiz A, et al. The effect of Ankaferd Blood Stopper on severe radiation colitis. Endoscopy 2009; 41: E321-E322.
20. Shorbagi A, Sivri B. Successful management of a difficult case of radiation proctopathy with Ankaferd Blood Stopper: a novel indication (with video). Gastrointest Endosc 2010; 72: 666-667.
21. Akalin I, Okur FV, Haznedaroglu IC, et al. Acute in vitro effects of ABS (Ankaferd hemostat) on the lymphoid neoplastic cells (B-CLL and RAJI tumor cell lines). UHOD 2014; 24(4): 253–259.
22. Mumcuoglu M, Akin DF, Ezer U, et al. Ankaferd Blood Stopper induces apoptosis and regulates PAR1 and EPCR expression in human leukemia cells. Egypt J Med Human Gen 2015; 16(1): 19–27.
23. Odabas ME, Erturk M, Cinar C, et al. Cytotoxicity of a new hemostatic agent on human pulp fibroblasts in vitro. Med Oral Patol Oral Cir Bucal 2011; 16(4): e584–e587.
24. Haznedaroglu BZ, Beyazit Y, Walker SL, et al. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Crit Rev Oncol Hematol 2012; 83(1): 21–34.
25. Turk S, Malkan UY, Ghasemi M, Hocaoglu H, Mutlu D, Gunes G, Aksu S and Haznedaroglu IC. Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines. SAGE Open Medicine 2017; 5: 1–7.
26. Kocyigit A, Guler EM, Haznedaroglu İC, and Malkan UY. Ankaferd hemostat induces DNA damage, apoptosis and cytotoxic activity by generating reactive oxygen species in melanoma and normal cell lines. Int J Clin Exp Med 2017; 10(2): 2116-2126.
27. Aktaş B, Başar O, Yılmaz B, Ekiz F, Altınbaş A,Coban S, Büyükçam F, Albayrak A, Giniş Z, Yüksel O, Delibaşı T. Serum M30 and M65 levels and effects of Ankaferd blood stopper in cerulein induced experimental acute pancreatitis model in rats. Int J Clin Exp Med 2014; 7: 1676.
28. Isler SC, Demircan S, Cakarer S, et al. Effects of folk medicinal plant extract Ankaferd Blood Stopper on early bone healing. J Appl Oral Sci 2010; 18: 409–414.
29. Turhan N, Kurt M, Akdogan M, Arhan M, Kekilli M and Haznedaroglu I. Topical ankaferd blood stopper administration to bleeding gastrointestinal carcinomas can control local hemorrhage and decrease tumor vascularizationInternational Society on Thrombosis and Haemostasis 2009; 7(2) 1–1204.